FDA review of dupilumab for chronic spontaneous urticaria

Published Date: 13 Mar 2023

The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

TULSA Is Effective in Long-Term Prostate Cancer Control.

2.

For fit patients with CLL, frontline venetoclax-ibrutinib improves survival.

3.

Pediatric high-grade gliomas: Research reveals effective targeting with avapritinib

4.

Childhood brain tumors develop early in highly specialized nerve cells, research reveals

5.

Radioligand Shows Promise in Metastatic Hormone-Sensitive Prostate Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot